|
【结 构 式】 
|
【分子编号】58766 【品名】(2S)-N-(3-{(2R,6S,9S,12R,15R,19R,22S,25R,31S,33aS,34S,39S,42R,44aS)-31-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,34-dihydroxy-9-(4-hydroxybenzyl)-15,25,39,42-tetrakis[(1R)-1-hydroxyethyl]-6-isopropyl-12-methyl-5,8,11,14,17,21,24,27,30,33,38,41,44-tridecaoxo-19-tridecylnonatriacontahydro-1H,5H,21H-dipyrrolo[2,1-o:2,1-x][1,4,7,10,13,16,19,22,25,28,31,34,37]oxadodecaazacyclotetracontin-22-yl}propyl)-2,5-diamino-N-(2-cyanoethyl)pentanamide 【CA登记号】 |
【 分 子 式 】C79H129N17O24 【 分 子 量 】1700.99344 【元素组成】C 55.78% H 7.64% N 14% O 22.57% |
合成路线1
该中间体在本合成路线中的序号：(VI)The Boc protecting groups of (V) were removed by treatment with trifluoroacetic acid yielding diamine (VI). Finally, the cyano group of (VI) was reduced by catalytic hydrogenation over Pd/C to afford the title compound.
| 【1】 Masubuchi, K.; et al.; Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitor. Part 2. Bioorg Med Chem Lett 2001, 11, 10, 1273. |
| 【2】 Okada, T.; et al.; Synthesis and antifungal activities of novel 1,3-beta-D-glucan synthase inhibitors. 223rd ACS Natl Meet (April 7 2002, Orlando) 2002, Abst MEDI 174. |
| 【3】 Okada, T.; Shimma, N.; Murata, T.; Masubuchi, K.; Kohchi, M. (Basilea Pharmaceutica AG); Novel cyclic cpds.. EP 1254161; WO 0153322 . |
| 【4】 Shimma, N.; Kobayashi, K.; Horii, I.; Yanagawa, A. (Basilea Pharmaceutica AG); Nasally administrable cyclic peptide compsns.. WO 0152894 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (V) | 58765 | C89H145N17O28 | 详情 | 详情 | ||
| (VI) | 58766 | (2S)-N-(3-{(2R,6S,9S,12R,15R,19R,22S,25R,31S,33aS,34S,39S,42R,44aS)-31-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-2,34-dihydroxy-9-(4-hydroxybenzyl)-15,25,39,42-tetrakis[(1R)-1-hydroxyethyl]-6-isopropyl-12-methyl-5,8,11,14,17,21,24,27,30,33,38,41,44-tridecaoxo-19-tridecylnonatriacontahydro-1H,5H,21H-dipyrrolo[2,1-o:2,1-x][1,4,7,10,13,16,19,22,25,28,31,34,37]oxadodecaazacyclotetracontin-22-yl}propyl)-2,5-diamino-N-(2-cyanoethyl)pentanamide | C79H129N17O24 | 详情 | 详情 |